Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Domenico Moro, Michael Schlander, Harry Telser, Oriol Sola-Morales, Michael David Clark, Andrew Olaye, Charlotte Camp, Mohit Jain, Thomas Butt & Sumeet Bakshi. (2022) Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2]. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 581-598.
Read now
Read now
Charalabos-Markos Dintsios. (2022) A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 283-297.
Read now
Read now
Markus Molitor & Charalabos-Markos Dintsios. (2021) Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 145-157.
Read now
Read now
Katherine Eve Young, Imen Soussi, Michiel Hemels & Mondher Toumi. (2017) A comparative study of orphan drug prices in Europe. Journal of Market Access & Health Policy 5:1.
Read now
Read now
Articles from other publishers (7)
Michael J. DiStefano, So-Yeon Kang, Farah Yehia, Christian Morales & Gerard F. Anderson. (2021) Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs. Value in Health 24:3, pages 397-403.
Crossref
Crossref
Franziska Worm & Charalabos-Markos Dintsios. (2020) Determinants of Orphan Drug Prices in Germany. PharmacoEconomics 38:4, pages 397-411.
Crossref
Crossref
C. M. Dintsios, F. Worm, J. Ruof & M. Herpers. (2019) Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree. Health Economics Review 9:1.
Crossref
Crossref
Philippe Van Wilder, Magali Pirson & Alain Dupont. (2019) Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium. European Journal of Clinical Pharmacology 75:7, pages 895-900.
Crossref
Crossref
Daria Korchagina, Szymon Jaroslawski, Guy Jadot & Mondher Toumi. 2019. Regulatory and Economic Aspects in Oncology. Regulatory and Economic Aspects in Oncology
109
142
.
Sandra Nestler-Parr, Daria Korchagina, Mondher Toumi, Chris L. Pashos, Christopher Blanchette, Elizabeth Molsen, Thomas Morel, Steven Simoens, Zoltán Kaló, Ruediger Gatermann & William Redekop. (2018) Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health 21:5, pages 493-500.
Crossref
Crossref
Safiyya Dharssi, Durhane Wong-Rieger, Matthew Harold & Sharon Terry. (2017) Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet Journal of Rare Diseases 12:1.
Crossref
Crossref